GlobeNewswire Inc | Feb 4, 2021 07:00AM EST

February 04, 2021

MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

TELA Bio's management is also scheduled to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021 at 4:30 PM EST. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.

TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing patients with advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bios OviTex and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. For more information, visit www.telabio.com.

TELA Bio ContactStuart HendersonVice President, Corporate Development and Investor RelationsTELA Bio, Inc.484-320-2930

Investor ContactGreg Chodaczek347-620-7010ir@telabio.com